Discovery of N-amido-phenylsulfonamide derivatives as novel microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors. 2021

Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
Research Institute for Basic Sciences and Department of Chemistry, College of Sciences, Kyung Hee University, Seoul 02447, Republic of Korea.

Our previous research showed that N-carboxy-phenylsulfonyl hydrazide (scaffold A) could reduce LPS-stimulated PGE2 levels in RAW 264.7 macrophage cells by an inhibition of mPGES-1 enzyme. However, a number of scaffold A derivatives showed the drawbacks such as the formation of regioisomers and poor liver metabolic stability. In order to overcome these synthetic and metabolic problems, therefore, we decided to replace N-carboxy-phenylsulfonyl hydrazide (scaffold A) with N-carboxy-phenylsulfonamide (scaffold B) or N-amido-phenylsulfonamide frameworks (scaffold C) as a bioisosteric replacement. Among them, MPO-0186 (scaffold C) inhibited the production of PGE2 (IC50: 0.24 μM) in A549 cells via inhibition of mPGES-1 (IC50: 0.49 μM in a cell-free assay) and was found to be approximately 9- and 8-fold more potent than MK-886 as a reference inhibitor, respectively. A molecular docking study theoretically suggests that MPO-0186 could inhibit PGE2 production by blocking the PGH2 binding site of mPGES-1 enzyme. Furthermore, MPO-0186 demonstrated good liver metabolic stability and no significant inhibition observed in clinically relevant CYP isoforms except CYP2C19. This result provides a potential starting point for the development of selective and potent mPGES-1 inhibitor with a novel scaffold.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071876 Prostaglandin-E Synthases Oxidoreductases that catalyze the GLUTATHIONE-dependent oxidoreduction of PROSTAGLANDIN H2 to PROSTAGLANDIN E2. Cytosolic Prostaglandin E2 Synthase,Endoperoxide Isomerase,PGE2 Isomerase,PGE2 Synthase,PGR2 E-Isomerase,PTGES2 Protein,PTGES3 Protein,Prostaglandin E Isomerase,Prostaglandin E Synthase,Prostaglandin E Synthase 1,Prostaglandin E Synthase 2,Prostaglandin E Synthase 3,Prostaglandin E Synthase-1,Prostaglandin E Synthases,Prostaglandin E2 Synthase,Prostaglandin Endoperoxide E Isomerase,Prostaglandin H2 E-Isomerase,Prostaglandin H2-Prostaglandin E2 Isomerase,Prostaglandin R2 E-Isomerase,Prostaglandin-E Synthase,E Synthases, Prostaglandin,Isomerase, Endoperoxide,Isomerase, PGE2,Isomerase, Prostaglandin E,PGR2 E Isomerase,Prostaglandin H2 E Isomerase,Prostaglandin H2 Prostaglandin E2 Isomerase,Prostaglandin R2 E Isomerase,Synthase, PGE2,Synthase, Prostaglandin E,Synthase, Prostaglandin E2,Synthase, Prostaglandin-E,Synthases, Prostaglandin E,Synthases, Prostaglandin-E
D000072283 A549 Cells An immortalized cell line derived from human ADENOCARCINOMA, ALVEOLAR basal epithelial cells isolated from the lungs of a male patient in 1972. The cell line is positive for KERATIN, can synthesize LECITHIN, and contains high levels of POLYUNSATURATED FATTY ACIDS in its PLASMA MEMBRANE. It is used as a model for PULMONARY ALVEOLI function and virus infections, as a TRANSFECTION host, and for PRECLINICAL DRUG EVALUATION. A549 Cell Line,A549 Cell,A549 Cell Lines,Cell Line, A549,Cell Lines, A549,Cell, A549,Cells, A549
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D055808 Drug Discovery The process of finding chemicals for potential therapeutic use. Drug Prospecting,Discovery, Drug,Prospecting, Drug

Related Publications

Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
April 2024, Bioorganic chemistry,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
May 2007, Journal of molecular modeling,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
January 2017, European journal of medicinal chemistry,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
August 2009, Journal of medicinal chemistry,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
July 2008, Journal of medicinal chemistry,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
July 2005, Bioorganic & medicinal chemistry letters,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
December 2010, Bioorganic & medicinal chemistry letters,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
February 2012, European journal of medicinal chemistry,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
December 2008, Journal of medicinal chemistry,
Misong Kim, and Geuntae Kim, and Minji Kang, and Dohyeong Ko, and Yunchan Nam, and Chang Sang Moon, and Heung Mo Kang, and Ji-Sun Shin, and Oliver Werz, and Kyung-Tae Lee, and Jae Yeol Lee
September 2015, Prostaglandins & other lipid mediators,
Copied contents to your clipboard!